N/A N=14 Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients
Covid19 · Respiratory Function Loss · Coronavirus Infection
Primary: Change in Peak Expiratory Flow (Absolute Value) — 175; 160 ml/min — p=0.374
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Dual MRI for Cardiopulmonary COVID-19 Long Haulers
Covid19
Primary: Red Blood Cell to Membrane (RBC:M) Ratio — 0.39; 0.51 ratio (RBC:M)
N/A N=44 Swallowing Impairment After COVID-19 Infection
Covid19
Primary: Number of Participants With Impaired Swallowing Safety — 3; 1 Participants — p=<0.001
N/A N=252 Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic
Covid19 · Critical Care · Postintensive Care Syndrome
Primary: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) — 5; 13.5 units on a scale
Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
N/A N=224 Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Prone Positioning · High Flow Nasal Cannula · Acute Respiratory Distress Syndrome
Primary: Treatment Failure (Intubation or Death) — 45; 45 Participants
Phase 1 N=80 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
COVID-19
Primary: Participants With Serious Adverse Events. — 12; 15 Participants
Phase 2 N=53 Nebulised Rt-PA for ARDS Due to COVID-19
COVID
Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)
Phase 4 N=63 Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
Cancer
Primary: Sniff Nasal Inspiratory Pressure (SNIP) — 90; 87; 89; 109 cmH20
N/A N=28 Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
Covid19
Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds
Phase 2 N=46 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
CoronaVirus Induced Disease-2019 (COVID-19)
Primary: Percentage of Participants Alive and Without Respiratory Failure Through Day 28 — 86.4; 79.2 percentage of participants — p==0.599
Phase 2 N=200 Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
SARS (Severe Acute Respiratory Syndrome) · Coronavirus
Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio
Phase 1 N=19 Electrical Stimulation for Critically Ill Covid-19 Patients
Covid19 · Muscle Atrophy · Muscle Weakness
Primary: Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 352; 323 milliVolts
N/A N=119 Myocardial Injury and Quality of Life After COVID-19
COVID-19 · Myocardial Injury · Myocarditis Post Infection
Primary: Percentage of Patients (%) Recovered From COVID-19 With a Decrease in the Global Contractility of the Left and Right Ventricles. — 19; 39; 48 Participants
Phase 2 N=99 Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19
COVID · Corona Virus Infection · Covid-19
Primary: Percent Change in D-dimer — -5.6; -2.4 percent daily change — p=0.24
N/A N=417 The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19
COVID-19
Primary: Mechanical Ventilation — 21 Participants
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
Phase 2 N=30 Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
Phase 2 N=19 Electrical Stimulation for Critically Ill Post-Covid-19 Patients
COVID-19 · Muscle Atrophy · Muscle Weakness
Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts
Phase 1 N=12 Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
Phase 3 N=22 Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Long COVID
Primary: Change in the Symptoms of Long COVID-19 Patients — 20.33; 27; 15.71; 22.43 units on a scale — p=0.200
Phase 2 N=101 The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
COVID-19
Primary: Number of Participants With Worsening of COVID-19 Within 28 Days — 1; 1 Participants
Phase 3 N=30 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
N/A N=33 Development of a Rehabilitation Strengthening and Mobility Program for Ventilator Dependent Older Patients
Respiration, Artificial · Critical Illness · Chronic Disease
Primary: Functional Assessment: Handgrip — 3.6; 1.3 kg
N/A N=12 Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate
Covid19
Primary: Flow Mediated Dilation of the Brachial Artery — 6.1; 6.2 % of brachial artery dilation
Phase 4 N=103 The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Pulmonary Fibrosis · Interstitial Lung Disease · Respiratory Disease
Primary: Change in Forced Vital Capacity (FVC) — 147.55; 167.72 mL
N/A N=120 Treatment of Critical Illness Polyneuromyopathy
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
N/A N=52 Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure
Respiratory Insufficiency · Depression · Rehabilitation
Primary: Feasibility Measure Per Participant — 0.8 proportion of intended visits
N/A N=93 Increasing Physical Activity in COPD Through Rhythmically Enhanced Music
COPD Patients and Patients Recovering From COVID19
Primary: Six-minute Walk Distance — 452; 429 meters — p=0.85